Status:
COMPLETED
Assessment of Treatment Patterns of Severe Asthmatic Patients Across the Gulf Region - SevEos Study
Lead Sponsor:
AstraZeneca
Conditions:
Severe Asthma
Eligibility:
All Genders
12+ years
Brief Summary
SevEos is a cross-sectional, multi-center, non-interventional study aimed to describe the treatment patterns in 250 severe asthma patients across the Gulf region. In addition, the study will determine...
Detailed Description
The primary objective of this study is to describe the treatments patterns of severe asthmatic patients across four Gulf countries during the past year. Secondary Objectives 1. To determine the curr...
Eligibility Criteria
Inclusion
- To be included in this study, patients (both male and female) must fulfill all of the following criteria:
- Age above 12 years.
- Body weight of ≥40 kg.
- Diagnosed by a physician with severe asthma, who requires regular treatment with medium or high dosage Inhaled Corticosteroids (ICS) (patients aged 12-17 years) OR high-dosage ICS ( plus Long-Acting Beta Agonist (LABA) for at least 1 year before enrolment.
- \[Note that the value of the medium/high dosage is dependent on the type of ICS
Exclusion
- Patients who meet any of the following criteria are ineligible to participate in the study:
- Patient refuses to consent.
- Another clinically important pulmonary disease is considered to be the primary diagnosis, other than severe asthma (i.e.: COPD, major bronchiectasis, active tuberculosis, and other conditions considered by the principal investigator).
- Mentally disabled patient or inability to understand the study questions.
- Unable to read/write.
Key Trial Info
Start Date :
December 31 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 3 2019
Estimated Enrollment :
253 Patients enrolled
Trial Details
Trial ID
NCT03387722
Start Date
December 31 2017
End Date
January 3 2019
Last Update
September 10 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Muscat, Oman, 111
2
Research Site
Dubai, United Arab Emirates